Extracorporeal support (ECMO) is indicated in severe heart or lung failure with 80% risk of mortality. In experienced centers, overall survival to discharge ranges from 40% in cardiac arrest (ECPR) to 70% for respiratory failure in adults, 80% in children and newborns with prolonged ECMO support, severe lung injury can recover to normal function, re-defining irreversible lung injury. In the future ECMO will be automatically controlled with care out of ICU or at home.
ECLS (ECMO) has been standard care for newborn infants and children with heart and lung disease since 1990, and for adults with cardiac and respiratory failure since 2009 [1] . There are currently over 70,000 cases in the ELSO Registry. 28,271 of these cases are newborn infants with respiratory failure [2] . 14,851 of these cases are patients managed with ECMO for severe respiratory failure in the pediatric (6929) and adult (7922) age groups [2] . The balance is cardiac support in children and adults. The survival (hospital discharge) for adults with severe respiratory failure in the last 5 years is 60%. The indications for ECLS are 80% risk of mortality, measured by appropriate parameters for each diagnosis and age group. Since the first cases in the early 70s until 2005, ECMO circuits were assembled on-site from a variety of devices. Despite the variation in devices, the technology was relatively standardized. Patients were deeply sedated, anticoagulated with heparin titration, and regular efforts were made at lung recruitment (often resulting in barotrauma and pneumothorax). Bleeding was the major complication. ECMO was often terminated on day 14, 21, 30 because the lung failure appeared permanent and irreversible. Transplantation was not an option. This era is referred to as ECMO 1.
Major changes in the technology occurred in 2008 with entire ECMO systems being developed by the Maquet, Sorin, and Novalung companies in Europe [3] [4] [5] . The Maquet devices were available in the United States in 2009. The new devices resulted in much safer, simpler, prolonged management of extracorporeal support and have led to a much wider use of ECMO in respiratory failure. Prior to 2009 there were fewer than 100 cases per year, and survival varied widely because of the small numbers in each diagnostic group. With the new devices there have been hundreds of cases each year and survival stabilized at about 60%. Improved devices have also resulted in a change in patient management emphasizing minimal sedation, spontaneous breathing, and active physical therapy. Bleeding is still the most common complication but is manageable. Lung recovery occurs regularly after as much as 1 or 2 months of minimal or even no lung function [6, 7] . Consequently, ''irreversible" lung failure is being re-defined. Bridging to lung transplantation is now a routine with ambulatory ECMO [8] . We refer to this era as ECMO 2. Patient management in ECMO 1 and ECMO 2 is demonstrated in Fig. 1 .
ECMO for cardiac support requires the venoarterial (VA) mode of access. VA includes right atrial and systemic artery cannulation, often done urgently during ECPR. Unique problems are perfusion to the distal leg when femoral artery access is used: left atrial venting if there is no cardiac function, and differential circulation if lung failure coincides with cardiac failure treated by femoral perfusion. VA perfusion is short (3-6 days) because the heart often recovers quickly, or not at all (about 10-20%). When there is no heart recovery in a day or two the patient should be converted to a VAD and considered for transplant. The overall survival from cardiac support is 30-50%. Many cases sustain irreversible brain injury prior to ECMO.
ECMO for respiratory failure in adults and older children is usually managed by venovenous (VV) access [9] . In VV access, blood is drained from the right atrium or SVC and IVC, and reinfused into the right atrium. This access puts the artificial lung in series with the normal lungs rather than in parallel (as in CPB or VA ECMO). The well-oxygenated infusion blood mixes with the native venous return (which did not pass through the ECMO circuit) so the resultant arterial PO 2 and saturation represents a mixture of the oxygenated extracorporeal blood and the unoxygenated venous blood which passes through the nonfunctional native lungs. This desaturated arterial blood combined with the normal cardiac output provides more than adequate systemic oxygen delivery to support metabolism, and the airway is managed at rest settings. With VV access the patient is reliant on his or her own hemodynamics, so cardiac output, pulmonary and systemic vascular resistance are unchanged during extracorporeal gas exchange.
Selective CO 2 removal
Membrane lungs are much more efficient at transferring CO 2 than adding oxygen. This is because the inlet minus outlet difference for oxygen is limited to around 5 ccO 2 /dL, but inlet/ outlet difference for CO 2 can be as high as 15-20 cc/dL. For this reason a large amount of CO 2 can be removed at much lower blood flow than what is required for oxygenation. Selective CO 2 removal in adults can be achieved with relatively low extracorporeal flows (500-1000 cc/min). Gattinoni reported a series of ARDS patients managed with extracorporeal CO 2 removal (ECCOR) in 1986 [10] . The technique of selective CO 2 removal has been investigated many times since that original publication. Selective CO 2 removal is ideal for the management of status asthmaticus and for COPD in exacerbation. It is currently being studied again for ARDS, with the intention of minimizing airway pressure and allowing oxygenation by insufflation into the airway. Although devices are being marketed specifically for CO 2 removal, any infant or pediatric system is fine for CO 2 clearance in adults.
Bridge to lung transplantation
In the past the requirement for ECMO was considered a contraindication to transplantation because the patients were in severe primary respiratory failure and became wasted and frail with the heavy sedation and paralysis. With the advent of ECMO 2 bridge to transplantation has become routine practice [8] . In fact, a patient listed for transplantation who is admitted for an exacerbation (formerly removed from the transplant list) can now be managed with ECMO using double lumen venovenous access, minimizing or eliminating sedation, and encouraging ambulation, nutrition and physical therapy, thus improving the status of the patient for subsequent transplantation [11] .
ECMO in the next 10 years
Vascular access
VA access using the femoral vessels is the method of choice for adults for cardiac support. VV access is preferred for respiratory failure. Currently, most venovenous access is achieved with the use of a double lumen catheter, draining blood from the vena cavae and right atrium and returning it to the right atrium, aiming the return infusion toward the tricuspid valve and right ventricle [12] . This approach will continue in the future with variations of the method of placement, imaging during placement, and new double lumen catheters. However there will always be a need for two-catheter venovenous access, draining from the femoral vessels and reinfusing into the right atrium. This technique can be accomplished very quickly at the bedside in an unstable patient, does not require radiographic imaging, and is the most reliable way to quickly establish venovenous access. When access is established in emergency situations in this fashion the cannulation is changed after a day or two to double lumen catheter via the jugular vein. This allows removal of the femoral venous catheter and facilitates ambulation.
The ECMO circuit
The next generation of ECLS pumps will emphasize automation and servo regulation, such that the desired extracorporeal flow is set and the pump will automatically achieve that flow despite a variety of conditions of the patient (coughing, activity, blood volume). In similar fashion, the arterial blood saturation will be used to servo regulate the flow with calculations comparing systemic oxygenation to extracorporeal flow and mixed venous saturation built into the program so that the desired arterial saturation will be reached automatically or, if it cannot be reached, a proposed solution will be displayed. Current membrane lungs are primarily square resulting in stagnation and thrombus formation in the corners. The next generation of devices will be round in all dimensions to minimize stagnation and thrombosis. The blood flow required for CO 2 removal for adults can be between 500 and 1000 cc/ min with a high sweep flow. The sweep flow itself will be servo regulated based on the exhaust gas CO 2 so that adjustments of the sweep flow will be automatic.
Anticoagulation
Current devices have nonthrombogenic coatings generally based on heparin on the surface. This minimizes the need for anticoagulation but does not eliminate it because the primary cause of clotting on the artificial surfaces is platelet adhesion and aggregation. The next generation of devices will have surfaces which inhibit platelet adhesion to the surface. Currently this is being done with nitric oxide eluting from the plastic [13] . The use of nitric oxide or similar materials to prevent platelet adhesion will greatly decrease the need for anticoagulation, and when combined with surface antifibrin chemicals, may eliminate the need for anticoagulation altogether. In the meantime, the anticoagulant of choice for ECLS may become direct thrombin inhibitors such as argatroban and bivalirudin [14] . Heparin has always been used for ECLS but is dependent on antithrombin for its activity and the response to heparin infusion is affected by many variables in the blood. Direct thrombin inhibitors are simpler and act directly on thrombin formation.
Patient management
With the automation and servo regulation in place, the primary person caring for the extracorporeal circuit and patient will be the bedside ICU nurse. Some extra training will be required, but the ECMO specialist will no longer need to be sitting continuously at the bedside [15] . There will be a need for ECMO specialists as the supervising team, educators, and management of the circuit and emergencies. It will become standard practice to have 10 or 20 patients on ECMO in any given hospital at any given time, including the full spectrum of ages and cardiac and respiratory support. For adult respiratory support management of ECMO in the ICU will be as routine as managing a patient on a ventilator or on renal replacement therapy is today. While most adult patients are on ECMO for 7-14 days, a significant fraction of patients will be on ECMO for a month or more awaiting lung recovery or perhaps transplantation. These patients are quite stable and can be managed in stepdown units. The fact that there may be several patients with respiratory failure on ECMO for a month or more will result in the establishment of regional lung failure centers which are equipped to manage a dozen or more chronic ECMO patients at a time, bridging to transplantation or to recovery. These units will be similar to the heart failure centers now common practice in major medical centers. ECMO patients will be managed in conventional hospital settings or perhaps even at home with appropriate monitors and alarms. This will be similar to the management of patients with ventricular assist devices at home which has evolved over the last 15 years.
Implantable (wearable) membrane lungs
Implantable membrane lungs are membrane devices attached by conduits directly to the circulation, either to the heart directly or to peripheral vessels. The membrane lungs themselves will be paracorporeal, attached to the access cannulas that pass through the skin. The reason for this is that the devices will have to be changed from time to time and, although they could be implanted subcutaneously or in the pleural space, the need for evaluation and replacement makes the paracorporeal position the most convenient for long term support. These implantable lungs may be used for bridging to transplantation and as destination therapy for end stage lung disease in patients who are not candidates for transplantation. Implantable membrane lungs can be used without the need for blood pumps, relying either on pulmonary artery pressure or systemic arterial pressure to drive blood through the device. For patients who require oxygenation as well as CO 2 clearance and for patients who are in right ventricular failure because of pulmonary hypertension, the implantable lung will be placed from the pulmonary artery to the left atrium [16] (Fig. 2) . This allows essentially all of the circulation to pass through the device depending on the relative resistances of the pulmonary vascular bed and the device. With high blood flows, full oxygenation and CO 2 removal can be achieved and the right ventricle is unloaded so the device also acts as treatment for pulmonary hypertension with right ventricular failure. PA to LA access was first used clinically in 2007 and has now been used in many patients primarily as a bridge to transplantation in patients who are in right ventricular failure [17] . This access works very well but requires a thoracotomy for placement of the access cannulas and always runs the risk of systemic embolization.
Devices attached to a major artery and vein, notable the subclavian or axillary artery and vein can achieve blood flows in the range of 20% of the cardiac output. This is sufficient to remove all the metabolically produced CO 2 and has the advantage of avoiding systemic arterial embolization. AV Figure 2 Pulmonary artery to left atrium implantable membrane lung.
implantable devices with paracorporeal placement of the lung will be used for end stage lung disease patients who are not candidates for transplantation. As destination therapy these devices will be used first for palliation of severe COPD. Because the goal is primarily CO 2 removal, the devices can be small in size and have a relatively small gas exchange surface area.
The application of the devices and techniques described above will result in the next generation of ECMO management, which we call ECMO 3 (Fig. 1) . The characteristics of ECMO 3 will be awake, extubated, spontaneously breathing patients, without systemic anticoagulation, managed in stepdown units, general care or even at home.
